<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Invasive mechanical ventilation in acute respiratory failure complicating chronic obstructive pulmonary disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Invasive mechanical ventilation in acute respiratory failure complicating chronic obstructive pulmonary disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Invasive mechanical ventilation in acute respiratory failure complicating chronic obstructive pulmonary disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gilman B Allen, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Polly E Parsons, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Umur Hatipoglu, MD, MBA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14987193"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Invasive mechanical ventilation is a means of life support typically reserved as a last option for acute respiratory failure in chronic obstructive pulmonary disease (COPD). Mechanical ventilation in this population is specifically associated with complications including dynamic hyperinflation and barotrauma that can lead to cardiovascular collapse and death.  </p><p>Details of invasive mechanical ventilation for acute respiratory failure in patients with COPD are discussed in this topic. The use of noninvasive positive pressure ventilation and other aspects of the management of acute respiratory failure in COPD are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.) </p><p class="headingAnchor" id="H14987200"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>The indications for intubating patients with chronic obstructive pulmonary disease (COPD) are similar to those for all patients with acute respiratory failure (eg, life-threatening respiratory distress, failure of oxygenation and ventilation). The decision to institute invasive mechanical ventilation in this population is typically based upon a constellation of clinical signs and symptoms in the context of the patient's preferences for life support. While in the past, patients were traditionally intubated late in the course of their acute illness (eg, respiratory arrest) clinical practice now supports earlier intubation. (See  <a class="medical medical_review" href="/z/d/html/268.html" rel="external">"The decision to intubate"</a> and  <a class="medical medical_review" href="/z/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a>.)  </p><p>The majority of patients with acute respiratory failure due to acute exacerbations of COPD (AECOPD) should undergo a trial of noninvasive mechanical ventilation (NIV) because intubation can be successfully avoided and mortality reduced with this intervention [<a href="#rid1">1-7</a>]. Exceptions include patients with contraindications to NIV, failure of NIV, and severe respiratory distress. These are summarized below. (See  <a class="medical medical_review" href="/z/d/html/1636.html" rel="external">"Noninvasive ventilation in adults with acute respiratory failure: Benefits and contraindications"</a>.)</p><p>This initial approach can take the form of noninvasive positive pressure ventilation (NIPPV) via nasal or full facemask, but can also be approached with oxygen delivered through high flow nasal cannula (HFNC). There are now data in patients with hypoxic respiratory failure that support the use of HFNC as a means of avoiding the need for intubation [<a href="#rid8">8</a>]. In fact, preliminary data suggest that HFNC may be more effective than NIPPV in avoiding the need for intubation, and is potentially associated with fewer long-term complications than NIPPV [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">"Continuous oxygen delivery systems for the acute care of infants, children, and adults", section on 'Nasal cannula'</a>.)</p><p class="headingAnchor" id="H87289233"><span class="h2">Life threatening respiratory failure</span><span class="headingEndMark"> — </span>Immediate intubation and mechanical ventilation should be considered in those with features of life-threatening respiratory failure. Examples of such patients include those with severe respiratory distress who are not suitable for NIV as well as those with agonal breathing, cardiopulmonary arrest, and concurrent severe hemodynamic instability [<a href="#rid9">9,10</a>]. </p><p>A bedside scoring system, BAP-65, that uses signs of respiratory distress, along with other risk factors, has been found to predict the need for mechanical ventilation in patients with acute exacerbations of COPD [<a href="#rid11">11,12</a>]. In one study, patients with four risk factors (elevated BUN, altered mental status, pulse &gt;109 beats/min, age &gt;65 years) were more likely to require mechanical ventilation compared to those with none of these risks (55 versus 2 percent).  </p><p class="headingAnchor" id="H4514118"><span class="h2">Failure of noninvasive ventilation</span><span class="headingEndMark"> — </span>Several studies in patients with AECOPD have shown that deteriorating or unaltered gas exchange despite NIV predicts the need for invasive mechanical ventilation [<a href="#rid6">6,13,14</a>]. In one multicenter prospective trial of 1033 patients with AECOPD, patients with the following features at initial presentation had a greater than 70 percent chance of failing NIV and requiring mechanical ventilation [<a href="#rid6">6</a>]: Glasgow Coma Score &lt;11, acute physiology and chronic health evaluation (APACHE) II score ≥29, respiratory rate ≥30, and pH &lt;7.25. After two hours of NIV, a pH &lt;7.25 further increased the likelihood of need for intubation from 70 to 90 percent. These data together with clinical experience support the need for close monitoring in an intensive care unit for patients with AECOPD initially treated with NIV. Interval evaluation at two hours should be considered so that timely escalation in the level of care from noninvasive to invasive ventilation can proceed. </p><p>Trends in practice and prognosis appear to favor use of NIV over IMV in COPD patients hospitalized for respiratory failure. Between 2001 and 2011, initial use of NIV over IMV has steadily increased by 15 percent annually while initial IMV use has steadily declined by 3.2 percent annually [<a href="#rid7">7</a>]. A cross-sectional analysis of 77,576 patients hospitalized in 386 hospitals between 2009 and 2011 demonstrated considerable hospital variation in the use of NIV as the initial mechanical ventilation strategy, with the majority turning to NIV before IMV [<a href="#rid15">15</a>]. This study demonstrated that higher rates of risk-standardized NIV use were associated with reduced hospital costs, shorter length of stay, and lower adjusted mortality compared with IMV [<a href="#rid15">15</a>]. A separate cohort of 25,628 patients with AECOPD throughout 420 hospitals found that 70 percent were initially treated with NIV. Compared with those initially on IMV, use of NIV was associated with lower rates of hospital acquired pneumonia, lower hospital costs, and a reduced length of stay after propensity matching. </p><p>While NIV has not been compared with high flow oxygen delivered via nasal cannula (HFNC), some experts are increasingly using HFNC in the setting of AECOPD. Whether this strategy definitively reduces intubation rates in patients with AECOPD is yet to be determined. Further details regarding HFNC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114077.html" rel="external">"Heated and humidified high-flow nasal oxygen in adults: Practical considerations and potential applications"</a>.)</p><p class="headingAnchor" id="H87289272"><span class="h2">Arterial blood gas abnormalities</span><span class="headingEndMark"> — </span>In patients with COPD, there are no absolute values on arterial blood gas (ABG) that determine when mechanical ventilation should be instituted. Typically, we consider intubation when the following gas exchange abnormalities are present, particularly after a trial of NIV:  </p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia that has not corrected with supplemental oxygen (failure to oxygenate)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe respiratory acidosis, unresponsive to therapy and/or NIV (failure to ventilate)</p><p></p><p>Many patients with COPD who present with acute respiratory failure have chronic hypoxia and/or hypercapnia due to their underlying disease or other comorbid conditions (eg, obesity hypoventilation). The interpretation of an ABG in this population should always be done in the context of prior baseline values when available, and the knowledge of influencing comorbidities. Additionally, paying attention to the presence of mixed acid-base disorders and calculating the predicted pH for acute and chronic acidosis should be done to avoid unnecessary intubation for chronic conditions. For example, a COPD patient with an arterial carbon dioxide tension (PaCO<sub>2</sub>) of 100 mmHg may appear alarming to the clinician at the bedside. However, if the pH is near normal (eg, 7.32) or there is evidence of a prior baseline PaCO<sub>2</sub> close to the measured value (eg, 90 mmHg), this suggests that the degree of acute hypercapnia is likely minor and intubation may potentially still be avoided. (See  <a class="medical medical_review" href="/z/d/html/1648.html" rel="external">"Arterial blood gases"</a> and  <a class="medical medical_review" href="/z/d/html/2352.html" rel="external">"Simple and mixed acid-base disorders"</a>.) </p><p class="headingAnchor" id="H14987214"><span class="h1">GOALS OF VENTILATOR MANAGEMENT</span><span class="headingEndMark"> — </span>The primary goals of invasive mechanical ventilation in patients with chronic obstructive pulmonary disease (COPD) are the following [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Correct derangements in oxygenation and ventilation</p><p class="bulletIndent1"><span class="glyph">●</span>Reduce the work of breathing</p><p class="bulletIndent1"><span class="glyph">●</span>Prevent dynamic hyperinflation (DHI) </p><p></p><p>The prevention of DHI is especially important in this population because DHI can lead to significant complications such as barotrauma, which can prolong the course of mechanical ventilation, and result in cardiovascular collapse or death. (See  <a class="medical medical_review" href="/z/d/html/1459.html" rel="external">"Dynamic hyperinflation in patients with COPD"</a> and <a class="local">'Dynamic hyperinflation'</a> below and  <a class="medical medical_review" href="/z/d/html/1628.html" rel="external">"Clinical and physiologic complications of mechanical ventilation: Overview", section on 'Auto-PEEP'</a>.) </p><p class="headingAnchor" id="H14987242"><span class="h1">VENTILATOR MODES</span></p><p class="headingAnchor" id="H322489511"><span class="h2">Commonly used modes</span><span class="headingEndMark"> — </span>A number of modes of mechanical ventilation can be used to ventilate patients with respiratory failure and chronic obstructive pulmonary disease (COPD). Volume or combined volume and pressure control modes of ventilation are commonly used. For this section, each mode of ventilation will be classified according to the most recently promoted taxonomy, based primarily upon its control variable, breath sequence, and targeting scheme [<a href="#rid17">17</a>]. It's important to note, however, that there are literally dozens of combinations of these three parameters, and despite sharing a similar combination of these parameters, such modes can carry different proprietary labels from one manufacturer to the next, as in the case of "CMV with autoflow" and "Pressure-regulated volume control." At the same time, modes that appear similar to one another across manufacturers can vary by the sake of subtle differences in their targeting schemes. For simplicity, this chapter will refer only to the basic taxonomy label dictated by the control variable and breath sequence. Although the optimal mode is unknown, we typically use the following volume-targeted modes: volume control continuous mandatory ventilation (VC-CMV), sometimes referred to as "assist-control," and synchronized intermittent mandatory ventilation (SIMV) or SIMV with pressure support ventilation (SIMV/PSV). Switching modes is not uncommon during the course of a patient's illness particularly when complications of mechanical ventilation, such as acute respiratory distress syndrome (ARDS) or barotrauma occur. </p><p>The advantages and disadvantages of the modes of ventilation typically used in patients with acute respiratory failure complicating COPD are reviewed in this section. The details of these modes as well as other modes of mechanical ventilation are reviewed separately.<strong> </strong>(See  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit"</a> and  <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">"Modes of mechanical ventilation"</a>.)</p><p class="headingAnchor" id="H2407173"><span class="h2">Volume-control (VC) and volume "targeted," pressure control (PC) modes</span><span class="headingEndMark"> — </span>In VC modes of ventilation, volume and flow are preset, such that ventilator-assisted breaths are triggered by either the ventilator (time) or the patient, and a set volume is delivered. For some modes, such as "CMV with autoflow," although a target volume is "preset," inspiratory pressure varies with breath to breath to achieve an average tidal volume using an adaptive targeting scheme, and is thus technically a pressure control (PC) mode (PC-CMV). </p><p class="headingAnchor" id="H9410337"><span class="h3">Volume control-continuous mandatory ventilation (VC-CMV)</span><span class="headingEndMark"> — </span>VC-CMV is a volume control mode that delivers a continuous mandatory breath sequence, with no allowance for spontaneous breaths. This translates to a preprogrammed number of mandatory breaths, triggered by time, with the allowance of additional patient-triggered mandatory breaths in between. By definition of being a volume control mode, both the tidal volume and flow are preset [<a href="#rid17">17</a>].When pressure is regulated breath to breath to achieve an average target volume during CMV, the mode is technically pressure control (PC-CMV). Both modes share similar objectives and drawbacks. </p><p>The key benefit from PC-CMV and VC-CMV modes is the ability to guarantee a predetermined minimum minute ventilation (set tidal volume multiplied by the set ventilator rate), which is generally high in patients with COPD due to abnormally increased physiologic dead space. Both modes can more easily meet this demand. The greatest disadvantage of these modes in patients with COPD is overventilation when the patient is tachypneic and frequently triggering breaths, all of which are mandatory in volume. Overventilation can lead to severe respiratory alkalosis and dynamic hyperinflation (DHI), which can lead to barotrauma, cardiovascular collapse, and even death. Among all modes, the work of breathing is lowest in patients receiving PC-CMV and VC-CMV [<a href="#rid18">18,19</a>]. However, the work of breathing on this mode can still be excessively high if the patient is not adequately sedated, is dyssynchronous with the ventilator, or has excessively high inspiratory flow demands [<a href="#rid20">20,21</a>]. Thus, in patients with COPD, careful selection of settings (to avoid excessively high minute ventilation), judicious use of sedatives (to decrease respiratory drive and work), and aggressive bedside monitoring (for DHI) are necessary for the success with these modes. (See <a class="local">'Dynamic hyperinflation'</a> below and  <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">"Modes of mechanical ventilation", section on 'Volume-limited ventilation'</a>.)</p><p class="headingAnchor" id="H14987250"><span class="h3">Intermittent mandatory ventilation (SIMV)</span><span class="headingEndMark"> — </span>An IMV breathing pattern can be delivered under volume or pressure control conditions (VC-IMV or PC-IMV, respectively) [<a href="#rid17">17</a>]. Most IMV is synchronized to patient effort (SIMV) using computer-controlled synchronization windows to better accommodate patient demands. Like VC-CMV, VC-IMV is programmed to deliver a predetermined minimum minute ventilation, using a preset rate of time-triggered mandatory breaths. However, unlike VC-CMV, VC-IMV is accompanied by windows of time that allow for additional spontaneous breaths, which are both triggered and cycled (terminated) by the patient. Each of these spontaneous breaths can either be entirely unsupported (VC-IMV) or partially assisted by pressure support (VC-IMVs,s) [<a href="#rid17">17</a>].</p><p>VC-IMV and PC-IMV, with or without pressure support, are alternative modes for use in patients with COPD who generate excessively high minute ventilation on CMV. Because not every breath is mandatory and preprogrammed in size, switching from CMV to IMV can reduce the risk of DHI and its attendant complications. Compared with CMV, this mode has been shown to be associated with greater work of breathing, which may offset some of the perceived benefits [<a href="#rid21">21,22</a>]. Notably, when patients have stabilized and liberation from mechanical ventilation is being planned, using an IMV mode should be discouraged, as this mode is associated with slower weaning from mechanical ventilation when compared to spontaneous breathing trials [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">"Modes of mechanical ventilation", section on 'Volume-limited ventilation'</a>.) </p><p class="headingAnchor" id="H14987257"><span class="h2">Pressure control-continuous spontaneous ventilation (PC-CSV)</span><span class="headingEndMark"> — </span>In this mode, commonly referred to as "pressure-support" ventilation, the breathing pattern is continuously spontaneous (CSV) with each breath being supported by a preset level of pressure (ie, pressure control [PC]). As a CSV mode, all breaths are patient triggered and cycled (terminated), and the volume of each spontaneous breath is variable, but augmented with PC support. </p><p>Unlike VC-CMV and VC-IMV, minute ventilation is determined by patient effort and respiratory mechanics, and consequently, a predetermined minute ventilation is not guaranteed. Work of breathing is also variable with PC-CSV. Depending on the level of support provided, work of breathing may be greater, equal to, or even less than that observed on CMV modes in patients ventilated predominantly for conditions other than COPD [<a href="#rid24">24</a>]. When compared with unsupported breaths ("pressure support" = 0) and IMV alone, incremental levels of pressure support in the low range (ie, between 0 and 60 percent of patient effort) decrease patient effort and work of breathing. However, the incremental benefit diminishes at higher levels of pressure support (&gt;60 percent of patient effort)  (<a class="graphic graphic_figure graphicRef71301" href="/z/d/graphic/71301.html" rel="external">figure 1</a>) [<a href="#rid18">18,19</a>]. Consistent with this observation, patients with COPD can become more dyssynchronous with the ventilator when higher levels of support are used  (<a class="graphic graphic_waveform graphicRef77977" href="/z/d/graphic/77977.html" rel="external">waveform 1</a>) [<a href="#rid25">25</a>]. </p><p>PPC-CSV is infrequently used to ventilate patients with COPD. This is, in part, because a predetermined minute volume cannot be set, and reduced work of breathing is not guaranteed with this mode, both of which are desirable in COPD [<a href="#rid18">18,19</a>]. In addition, minute ventilation may be insufficient during PC-CSV in patients with COPD because airway resistance is high. Since each breath is spontaneous, pressure support typically cycles off below a threshold of inspiratory effort (flow), and since high airway resistance results in decreased airflow during inspiration, this can cause inspiration to terminate prematurely before the optimal tidal volume has been delivered [<a href="#rid9">9,26</a>]. PSV also does little to avoid auto-PEEP (the product of dynamic hyperinflation), which when left untreated, can lead to increased patient work and barotrauma [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1651.html" rel="external">"Modes of mechanical ventilation", section on 'Pressure support'</a>.)</p><p class="headingAnchor" id="H32523892"><span class="h1">VENTILATOR SETTINGS</span></p><p class="headingAnchor" id="H322490005"><span class="h2">Initial ventilator settings and monitoring</span><span class="headingEndMark"> — </span>The ideal ventilator settings in patients with acute respiratory failure complicating chronic obstructive pulmonary disease (COPD) are those that meet the goals of mechanical ventilation: normalizing oxygenation and ventilation, reducing the work of breathing, and avoiding dynamic hyperinflation. The settings will vary according to the cause of acute respiratory failure as well as the mode of mechanical ventilation selected, which is VC-CMV or PC-CMV. Although not absolute, we typically initiate mechanical ventilation with the following initial settings for each mode:</p><p class="bulletIndent1"><span class="glyph">●</span>VC/PC-CMV – For patients in whom CMV is chosen as the initial mode of ventilation, we typically use the following settings: </p><p class="bulletIndent2"><span class="glyph">•</span>Fraction of inspired oxygen (FiO<sub>2</sub>) to maintain the oxygen saturation of hemoglobin (SO<sub>2</sub>) above 92 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tidal volume – 6 to 8 mL/kg (lower starting tidal volumes of 4 to 6 mL/kg may be preferred in COPD patients ventilated for ARDS)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ventilator rate – 10 to 16 breaths per minute.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Minute ventilation – Taking into consideration the aforementioned tidal volumes and rates, target minute ventilation could range from 60 to 128 mL/kg, but one would typically match a slightly higher rate with a lower tidal volume. One must also take into consideration the patient's physiologic dead space, which will be higher in COPD, and the dead space to tidal volume ratio, which will increase with smaller tidal volumes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Positive end expiratory pressure (PEEP) – 5 to 10 cm H<sub>2</sub>O.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inspiratory flow – 60 L/min.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trigger sensitivity – -1 to -2 cm H<sub>2</sub>O when pressure triggering is used or 2 L/min when flow triggering is used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VC/PC-IMV – For patients in whom volume control, synchronized intermittent mandatory ventilation with pressure support (VC-IMVs) is chosen as the initial mode of ventilation, we typically use similar settings to those of VC-CMV listed above, with the addition of pressure support (5 to 10 cm H<sub>2</sub>O) for spontaneous breaths taken by the patient above the set rate. The pressure support can be subsequently increased as needed for patient comfort and reduced when mitigation of respiratory alkalosis is the objective of using IMV support. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PC-CSV – Should this mode be chosen, we generally increase the pressure support level until the patient's respiratory rate falls below 30 breaths per minute (no ventilator or time trigger exists in CSV). However, when using PC-CSV, achieving the optimal pressure support level can be difficult in COPD. This is because the expiratory effort ("fighting the ventilator"), and consequently the respiratory rate, of patients with COPD may actually increase when the level of support is increased [<a href="#rid27">27</a>]. There is some evidence, with noninvasive modes, that PC-CSV can be less effective than VC/PC-CMV modes in reducing work of breathing, but can be perceived (by the observing provider) as being "more comfortable" to patients, likely because of "spontaneous" breaths being triggered and cycled by the patient [<a href="#rid28">28</a>]. This suggests it may be reasonable to transition COPD patients over from VC/PC-CMV to PC-CSV (with sufficient pressure support to conserve work of breathing and keep respiratory rate less than 30) once these patients have had sufficient time to recover from the more severe phase of their exacerbation. The FiO<sub>2</sub>, applied PEEP, inspiratory flow, and trigger sensitivity are chosen similarly to those of AC-CMV. </p><p></p><p>Due to abnormally high physiologic dead space, patients with COPD will often have higher than expected minute ventilation requirements and increased carbon dioxide retention, which typically improves over the patient's course [<a href="#rid29">29,30</a>]. The initial settings should be adjusted to satisfy the patient's minute ventilation requirement. Adjusting ventilator settings according to ABG results alone is problematic because these data provide no information regarding the work of breathing, which may be excessive, even when gas exchange is acceptable [<a href="#rid21">21</a>]. Subsequent adjustments to ventilator settings are best made at the bedside, according to the patient's response, respiratory effort, the presence of auto-PEEP, as well as arterial blood gas values (usually done within 30 minutes of any major adjustment).</p><p class="headingAnchor" id="H4927661"><span class="h2">Fraction of inspired oxygen</span><span class="headingEndMark"> — </span>Based upon findings from a systematic review, in which it was found that supplemental oxygen delivered to patients with normal oxygen saturation was associated with increased mortality [<a href="#rid31">31</a>], and an expert consensus panel guideline for supplemental oxygen delivery in acutely hospitalized patients [<a href="#rid32">32</a>], we advocate that supplemental oxygen be held or down-titrated for a peripheral oxygen saturation (SpO<sub>2</sub>) of greater than 96 percent. Because their recommendation for the lower limits of an SpO<sub>2</sub> threshold for starting supplemental oxygen therapy were largely informed by trials involving patients with stroke or myocardial infarction, the consensus panel was uncertain as to how to guide therapy for patients outside of this cohort. Nevertheless, given the nonlinear and steep nature of the hemoglobin dissociation curve below an SpO<sub>2</sub> of 90 percent, logic would dictate that supplemental oxygen be provided for COPD patients at an SpO<sub>2</sub> of 90 percent or below, and titrated to between 93 and 96 percent. These settings provide a safe cushion against dangerous desaturations in oxygenation, while at the same time avoiding any potential toxicity from high levels of oxygen [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/1622.html" rel="external">"Adverse effects of supplemental oxygen"</a> and  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Fraction of inspired oxygen'</a>.)</p><p>Typically, it is safe to adjust the FiO<sub>2</sub> while continuously monitoring SpO<sub>2</sub> by pulse oximetry. However, the clinician should periodically check SpO<sub>2</sub> measured by arterial blood gas co-oximetry due to the inaccuracy of peripheral monitoring in select circumstances (eg, nail polish, African Americans). (See  <a class="medical medical_review" href="/z/d/html/1612.html" rel="external">"Pulse oximetry"</a>.)</p><p>Hypoxemia is rarely refractory to supplemental oxygen in patients with exacerbations of COPD. However, this does not apply to patients with COPD who are ventilated for conditions characterized by high degrees of shunt physiology (eg, acute respiratory distress syndrome or patent foramen ovale). (See  <a class="medical medical_review" href="/z/d/html/1647.html" rel="external">"Measures of oxygenation and mechanisms of hypoxemia"</a> and  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a>.)</p><p class="headingAnchor" id="H322490066"><span class="h2">Tidal volume</span><span class="headingEndMark"> — </span>The optimal tidal volume for patients with acute respiratory failure complicating COPD is unknown and is largely determined by the etiology of respiratory failure. A low tidal volume strategy (eg, 4 to 6 mL/kg) is beneficial in patients with acute respiratory distress syndrome (ARDS) and is appropriate for COPD patients who are mechanically ventilated for ARDS. For patients with COPD who are ventilated due to other reasons, tidal volumes in the low range (eg, 6 to 8 mL/kg) may be tried as an initial strategy, although the benefit is less proven. The rationale for this approach is based upon the known high minute ventilation requirements in patients with COPD and the desire to avoid overdistension, dynamic hyperinflation, and lung injury in these patients, who are already at risk for these complications. (See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults", section on 'Low tidal volume ventilation: Initial settings'</a> and  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Tidal volume'</a>.)</p><p class="headingAnchor" id="H506326222"><span class="h2">Ventilator rate</span><span class="headingEndMark"> — </span>The optimal ventilator rate for patients with acute respiratory failure complicating COPD is not established and is largely determined by the patient's native respiratory rate. The ventilator rate (VR) refers to the number of breaths per minute that is set by the clinician on the ventilator (mandatory breaths). The spontaneous rate (SR) refers to the number of breaths per minute that a patient receives beyond the set ventilator rate (non-mandatory breaths). The patient's respiratory rate (RR) refers to the total number of breaths that the patient receives in one minute (RR = VR + SR). Although there is no desired upper or lower limit, we typically aim for RR &lt;25 (ideally &lt;20) and &gt;8 to 10 breaths per minute. (See  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Ventilator rate'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>During ACV, as a general rule, the VR is often set four breaths per minute less than the RR (eg, VR is set at 16 when the patient's RR is 20 breaths per minute). However, the patient should be monitored closely because a particularly high respiratory rate will decrease the expiratory time. This can worsen dynamic hyperinflation and result in inverse ratio ventilation (ie, inspiratory time is longer than the expiratory time), which is not desirable in COPD. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During SIMV, the initial VR is typically set to ensure at least 80 percent of the patient's total minute ventilation (RR multiplied by tidal volume) is delivered by the ventilator. For example, if the patient's minute ventilation is recorded by the ventilator at 10 L/min with a set tidal volume of 0.4 L, then the rate would be set at 20 breaths per minute (20 x 0.4 = 8 L).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A ventilator rate is not set during PSV.</p><p></p><p>The target rate is frequently adjusted to target a total minute ventilation (tidal volume multiplied by rate) of 115 mL/kg. The set rate can be decreased as needed to mitigate dynamic hyperinflation. (See <a class="local">'Dynamic hyperinflation'</a> below.)</p><p class="headingAnchor" id="H322490033"><span class="h2">Applied PEEP</span><span class="headingEndMark"> — </span>It is now recognized that applied PEEP may be beneficial in patients with expiratory airflow limitation (eg, COPD), despite past concerns that applied PEEP at any level could worsen dynamic hyperinflation (also known as auto-PEEP). Ideally, the application of extrinsic PEEP should slightly "undermatch" intrinsic PEEP so as to avoid worsening of auto-PEEP. In other words, extrinsic PEEP should never be more than intrinsic PEEP. In practice this is difficult to achieve because intrinsic PEEP is dynamic and fluctuates over time, often decreasing with therapy. Traditionally in the past, applied PEEP at levels no greater than 80 percent of intrinsic PEEP was advised, given the difficulty of actually measuring intrinsic PEEP in this population, together with the dynamic nature of auto-PEEP, and the harmful effects of too much applied PEEP. We now typically initially set PEEP at 5 to 10 cm H<sub>2</sub>O and adjust accordingly depending on the patient's course. Alternatively, starting at 5 cm H<sub>2</sub>O and increasing PEEP only if ineffective trigger efforts are observed can also be effective. Ineffective efforts are due to the patient having to overcome intrinsic PEEP before their effort is sensed by the ventilator. Ineffective efforts can often be alleviated with applied, extrinsic PEEP (provided it is not equal or greater than the intrinsic PEEP), which in turn may actually help to corroborate suspicions regarding the presence of auto-PEEP. For example, resolution of ineffective efforts with applied extrinsic PEEP can help confirm the presence of auto-PEEP and act as a guide to avoid the application of excessive extrinsic PEEP. (See  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)"</a> and <a class="local">'Prevention and treatment'</a> below.) </p><p class="headingAnchor" id="H4927668"><span class="h2">Inspiratory flow rate</span><span class="headingEndMark"> — </span>As a general rule, we suggest that the initial inspiratory flow rate be set at 60 L/min. The rate can then be adjusted (usually increased) if the patient appears to be dyssynchronous due to a high work of breathing (ie, higher inspiratory flow demand) or has dynamic hyperinflation. (See <a class="local">'Dynamic hyperinflation'</a> below and  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Flow rate and pattern'</a>.)</p><p>A high inspiratory flow rate (60 to 100 L/min) is generally advised in mechanically ventilated patients with COPD, to decrease the work of breathing and reduce the risk of dynamic hyperinflation (DHI) [<a href="#rid34">34-36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The inspiratory work necessary to overcome pulmonary and ventilator resistance in COPD is markedly increased if the inspiratory flow is insufficient. This is because patients with COPD generally have an increased respiratory (and inspiratory flow) demand. Increasing the inspiratory flow rate will often satisfy this high demand and decrease the work of breathing [<a href="#rid34">34,35,37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A high inspiratory flow rate is necessary to shorten inspiratory time and hence prolong expiratory time. A prolonged expiratory time is critical in patients with expiratory airflow limitation, by giving the patient time to fully exhale a delivered breath. As a result of complete or near complete exhalation, the likelihood of dynamic hyperinflation and consequent auto-PEEP decreases.</p><p></p><p>A high inspiratory flow rate is occasionally associated with an increase in the spontaneous respiratory rate, which has the potential to worsen dynamic hyperinflation [<a href="#rid35">35,38</a>]. However, the benefits of prolonged expiratory time appear to outweigh this risk. In one study of patients with COPD, increasing the inspiratory flow rate from 30 to 90 L/minute increased the respiratory rate from 16 to 20 breaths per minute  (<a class="graphic graphic_figure graphicRef56446" href="/z/d/graphic/56446.html" rel="external">figure 2</a>) [<a href="#rid35">35</a>]. However, despite an increase in respiratory rate, the net effect of increased inspiratory flow was to prolong expiratory time (2.1 to 2.3 seconds) and reduce auto-PEEP (7 to 6.4 cm H<sub>2</sub>O). </p><p>Although the main purpose of increasing inspiratory flow is a prolongation of the expiratory time, in many cases, greater prolongation of the expiratory time can be achieved by suppressing the patient's intrinsic respiratory drive and decreasing the respiratory rate. (See <a class="local">'Prevention and treatment'</a> below.) </p><p class="headingAnchor" id="H16711899"><span class="h2">Trigger sensitivity</span><span class="headingEndMark"> — </span>Ventilators can be triggered to deliver a breath by either a change in airway opening pressure (ie, pressure triggered) or flow (ie, flow triggered)  (<a class="graphic graphic_figure graphicRef93545" href="/z/d/graphic/93545.html" rel="external">figure 3</a>). Most modern ventilators today use flow triggering, integrated with a continuous low-level bias flow. We do not have a preference for pressure or flow triggering in patients receiving CMV. Inappropriate breaths may be initiated if the trigger setting is too sensitive, which can cause respiratory alkalosis. Conversely, the work of breathing may be increased if the trigger setting is not sensitive enough. (See  <a class="medical medical_review" href="/z/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Trigger sensitivity'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The trigger sensitivity is usually set at -1 to -2 cm H<sub>2</sub>O when pressure triggering is used. This means that ventilator-assisted breaths will be triggered when the airway pressure decreases to 1 to 2 cm H<sub>2</sub>O below atmospheric pressure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The trigger sensitivity is usually set at 2 L/min when flow triggering is used. This means that ventilator-assisted breaths will be triggered once the patient's inspiratory effort generates a flow of 2 L/min above the bias flow running through the circuit. </p><p></p><p>When using an IMV setting and relying heavily upon patient-triggered spontaneous breaths, it may be preferable (when given a choice) to favor flow triggering. In patients receiving IMV, total inspiratory effort is 30 to 40 percent less with flow triggering than pressure triggering [<a href="#rid39">39,40</a>]. In contrast, in patients receiving PC-CSV, inspiratory effort during triggering is only 10 percent less with flow triggering than pressure triggering [<a href="#rid41">41</a>]. However, this is of minimal clinical importance because the difference occurs during triggering only, which is a small part of the total inspiratory effort [<a href="#rid19">19,41</a>]. Inspiratory work does not appear to be impacted by the triggering method during ACV [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H588202"><span class="h1">DYNAMIC HYPERINFLATION</span></p><p class="headingAnchor" id="H16712533"><span class="h2">Auto-PEEP</span><span class="headingEndMark"> — </span>Dynamic hyperinflation (DHI) is characterized by increased levels of intrinsic positive end-expiratory pressure (PEEPi or "auto-PEEP"). The hyperinflation is progressive (dynamic) because air accumulates in the lung with each breath as a result of a failure to achieve complete exhalation before the onset of the next breath  (<a class="graphic graphic_figure graphicRef78052" href="/z/d/graphic/78052.html" rel="external">figure 4</a>). In patients with COPD who are intubated for respiratory failure, DHI can occur as a consequence of airflow obstruction due to bronchoconstriction, combined with a higher than normal minute ventilation (respiratory rate multiplied by tidal volume) delivered by the ventilator. DHI (spontaneous or ventilator-induced) creates elevated levels of auto-PEEP, which can lead to patient-ventilator dyssynchrony and increased work of breathing  (<a class="graphic graphic_figure graphicRef52671" href="/z/d/graphic/52671.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef59751" href="/z/d/graphic/59751.html" rel="external">figure 6</a>) barotrauma, cardiovascular collapse, and potentially even death. (See  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)", section on 'Potential sequelae'</a> and  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)", section on 'Auto (intrinsic) PEEP'</a>.) </p><p>Auto-PEEP is common in patients with COPD. In a prospective cohort study of 13 patients with COPD who were being mechanically ventilated, all of the patients had measurable auto-PEEP (mean 9.4 cm H<sub>2</sub>O), and seven had an auto-PEEP greater than 10 cm H<sub>2</sub>O [<a href="#rid42">42</a>]. Auto-PEEP is responsible for up to one-third of the total work of breathing in patients mechanically ventilated with COPD [<a href="#rid43">43</a>]. </p><p>Auto-PEEP can be detected in a number of ways. One practical and reliable method in patients with COPD is the demonstration on ventilator graphics of a progressive rise in peak airway pressures during mandatory volume-targeted ventilation [<a href="#rid44">44-47</a>]. Alternatively, ventilator time-flow graphics may demonstrate the commencement of inspiratory flow before expiratory flow reaches zero  (<a class="graphic graphic_figure graphicRef93546" href="/z/d/graphic/93546.html" rel="external">figure 7</a> and <a class="graphic graphic_figure graphicRef78052" href="/z/d/graphic/78052.html" rel="external">figure 4</a>). These methods are not quantitative. While auto-PEEP can be quantitatively assessed by measuring airway opening pressure during an end-expiratory pause (Paw)  (<a class="graphic graphic_waveform graphicRef57873" href="/z/d/graphic/57873.html" rel="external">waveform 2</a>) [<a href="#rid48">48</a>], this method is only accurate when the patient is paralyzed or exhibiting negligible abdominal and chest wall muscle engagement during exhalation, which is uncommon in COPD patients requiring mechanical ventilation [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)", section on 'Assessment'</a>.)</p><p class="headingAnchor" id="H1578897"><span class="h2">Prevention and treatment</span><span class="headingEndMark"> — </span>In patients with COPD who are mechanically ventilated, the prevention and treatment of DHI are primarily achieved through a reduction in respiratory rate and/or tidal volume, raising the inspiratory flow rate (both prolonging expiratory time), and treating the underlying airflow obstruction when present [<a href="#rid16">16</a>]. In addition, the application of extrinsic PEEP can potentially reduce the work of breathing (WOB)  (<a class="graphic graphic_figure graphicRef72568" href="/z/d/graphic/72568.html" rel="external">figure 8</a>) and improve patient-ventilator synchrony through a reduction in ineffective triggering attempts by the patient  (<a class="graphic graphic_figure graphicRef59751" href="/z/d/graphic/59751.html" rel="external">figure 6</a>) [<a href="#rid42">42,46,49</a>]. Thus, the simultaneous manipulation of settings to achieve this balance should reduce ventilatory dyssynchrony and work of breathing, as well as decrease auto-PEEP and its attendant complications [<a href="#rid19">19,25,34,47</a>]. (See  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)", section on 'Treatment'</a> and <a class="local">'Ancillary therapy'</a> below.) </p><p>When addressing DHI in a mechanically ventilated patient with COPD, the following should be considered:</p><p class="bulletIndent1"><span class="glyph">●</span>Reduce minute ventilation and prolong expiratory time – Because the main determinants of auto-PEEP are minute ventilation (Ve) and expiratory time (Te), the key strategies to limiting auto-PEEP focus on reducing total Ve, prolonging expiratory time, and improving expiratory flow [<a href="#rid45">45,50-53</a>]. This is primarily achieved through a reduction in respiratory rate and/or or tidal volume (the determinants of Ve) and raising the inspiratory flow rate (shortens inspiratory time [Ti] and prolongs Te)  (<a class="graphic graphic_figure graphicRef56446" href="/z/d/graphic/56446.html" rel="external">figure 2</a>). The consequent practice of permissive hypercapnia in this approach is acceptable, provided the arterial pH does not fall below 7.20 or lead to hemodynamic instability. (See <a class="local">'Tidal volume'</a> above and <a class="local">'Ventilator rate'</a> above and <a class="local">'Inspiratory flow rate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adjust inspiratory trigger sensitivity to reduce ineffective triggering and lower the degree of wasted work of breathing (WOB) – Ineffective triggering and consequently high WOB and dyssynchrony are common in states of severe airflow limitation such as COPD. Mitigating patient-ventilator dyssynchrony and high WOB relies primarily upon optimizing the trigger sensitivity for inspiration [<a href="#rid19">19,20,22,54</a>]. In patients with COPD, ineffective triggering can be reduced by making sure the patient's intrinsic inspiratory time closely matches the duration of the tidal breath delivered by the ventilator in order to avoid active exhalation against the machine-driven breath  (<a class="graphic graphic_waveform graphicRef77977" href="/z/d/graphic/77977.html" rel="external">waveform 1</a>) [<a href="#rid20">20,25</a>]. Inspiratory work can be reduced by adjusting the trigger sensitivity (usually flow triggered) to the lowest level needed to initiate a breath yet is ideally high enough to avoid false-triggering and overventilation (also known as "auto-cycling")  (<a class="graphic graphic_figure graphicRef93545" href="/z/d/graphic/93545.html" rel="external">figure 3</a>) [<a href="#rid47">47,55-57</a>]. (See <a class="local">'Trigger sensitivity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Apply extrinsic PEEP – In patients mechanically ventilated with COPD, the application of extrinsic PEEP has been shown to decrease WOB and improve patient-ventilator synchrony  (<a class="graphic graphic_figure graphicRef52671" href="/z/d/graphic/52671.html" rel="external">figure 5</a> and <a class="graphic graphic_figure graphicRef72568" href="/z/d/graphic/72568.html" rel="external">figure 8</a>) although it may not decrease DHI per se [<a href="#rid46">46,58,59</a>]. This is primarily due to a decrease in the energy required by the patient to reduce the airway pressure to trigger ventilator-assisted breaths. As an example, consider a patient whose trigger value is set to -2 cm H<sub>2</sub>O and whose auto-PEEP is 10 cm H<sub>2</sub>O. Without extrinsic PEEP, a breath will be triggered at an airway pressure of -2 cm H<sub>2</sub>O, which requires that the patient decrease the alveolar pressure to the same level (by 12 cm H<sub>2</sub>O). In contrast, when extrinsic PEEP of 5 cm H<sub>2</sub>O is applied, a breath will be triggered at an airway pressure of 3 cm H<sub>2</sub>O (ie, a -2 cm H<sub>2</sub>O pressure differential below 5 cm H<sub>2</sub>O), which requires that the patient decrease the alveolar pressure by only 7 cm H<sub>2</sub>O. (See <a class="local">'Applied PEEP'</a> above and  <a class="medical medical_review" href="/z/d/html/1642.html" rel="external">"Positive end-expiratory pressure (PEEP)", section on 'Applied (extrinsic) PEEP'</a>.)</p><p></p><p>Although DHI can be prevented and treated with the above maneuvers, occasionally, patients present with life-threatening auto-PEEP causing cardiovascular collapse from reduced venous return. Severe auto-PEEP should be suspected in any intubated COPD patient who has acute hypotension in the setting of a rapid breathing rate or rising peak airway pressures. Importantly, when suspected, <strong>immediate disconnection</strong> of the endotracheal tube from the ventilator is a potentially life-saving maneuver, and is the most effective means of testing for and abolishing hemodynamically significant auto-PEEP.</p><p class="headingAnchor" id="H16713704"><span class="h1">ANCILLARY THERAPY</span><span class="headingEndMark"> — </span>In addition to optimized ventilator settings, patients must be treated for the primary cause of their respiratory failure. Patients with severe obstruction from acute exacerbations of chronic obstructive pulmonary disease (AECOPD) should be aggressively treated with bronchodilators, glucocorticoids and antibiotics. <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">Acetazolamide</a> for the elimination of carbon dioxide does not appear to be of benefit [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a> and  <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H16713747"><span class="h2">Bronchodilators</span><span class="headingEndMark"> — </span>Patients with COPD who require mechanical ventilation should be given aerosolized bronchodilators to relieve acute and/or chronic obstruction. Beta-agonist and anti-cholinergic bronchodilators can be effectively delivered via metered dose inhalers (MDIs) or nebulizers during invasive mechanical ventilation using devices that can be attached to the inspiratory limb of the ventilator [<a href="#rid61">61-65</a>]. When compared to nebulized bronchodilators, MDI delivery results in sufficient bronchodilation when administered in higher than usual doses (eg, 4 to 8 puffs). MDIs are typically preferred because they are easy to use and are potentially less likely to result in ventilator tube contamination and ventilator-associated pneumonia. </p><p>The principles of bronchodilator use in patients mechanically ventilated with COPD are similar to that in patients with stable COPD or acute AECOPD, which are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults", section on 'Mechanically ventilated patients'</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Emergency department and hospital management'</a>.)</p><p class="headingAnchor" id="H16713759"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids are not routinely administered to patients who are mechanically ventilated with COPD unless they have an AECOPD. In AECOPD, systemic glucocorticoids reduce inflammation and relieve obstruction. While glucocorticoids have been shown to benefit nonventilated patients, the same mortality benefit has not been clearly reported in mechanically ventilated patients. A multicenter randomized study of 354 patients who required ventilatory support for AECOPD (noninvasive and invasive mechanical ventilation) demonstrated that compared to placebo, the administration of systemic glucocorticoids resulted in lower rates of NIV failure (0 versus 37 percent), shorter duration of mechanical ventilation (3 versus 4 days) and reduced length of ICU stay (6 versus 7 days) [<a href="#rid66">66</a>]. A single center trial demonstrated reduced additional days to weaning from mechanical ventilation (4.6 versus 7.2 days) and improved respiratory compliance in "difficult to wean" COPD patients (enrolled on average at day 6 of mechanical ventilation) using scheduled nebulized <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> [<a href="#rid67">67</a>]. </p><p>The dose and route of administration of glucocorticoids are similar in mechanically ventilated and non-mechanically ventilated COPD patients. The management of AECOPD with glucocorticoids is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Glucocorticoids in moderate to severe exacerbations'</a>.)</p><p class="headingAnchor" id="H257566008"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Antibiotics are not routinely administered for patients who are mechanically ventilated for COPD unless they have an acute exacerbation of COPD (AECOPD) or another indication for antibiotics, such as pneumonia. The rationale for this strategy for patients with AECOPD is derived from randomized studies and meta-analyses that report mortality benefits associated with antibiotic use, as well as reduced rates of readmission and shorter duration of mechanical ventilation. However, similar studies also report increased rates of infection with more virulent bacterial pathogens, as well as increased readmission rates for <em>Clostridium difficile</em> infection.  </p><p>The use of antibiotics in AECOPD is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.)  </p><p class="headingAnchor" id="H3213446027"><span class="h2">Acetazolamide</span><span class="headingEndMark"> — </span>Metabolic alkalosis, both acute and chronic compensatory, is commonly encountered among patients with AECOPD on invasive mechanical ventilation (IMV), either due to chronic carbon dioxide (CO<sub>2</sub>) retention, or interventions commonly encountered in the ICU, such as nasogastric suctioning, diuretic and/or glucocorticoid use, or even permissive hypercapnia. Concerns for metabolic alkalosis prolonging the weaning process via central respiratory drive suppression has led many clinicians to employ <a class="drug drug_general" data-topicid="9268" href="/z/d/drug information/9268.html" rel="external">acetazolamide</a> in an effort to reverse metabolic alkalosis (via renal bicarbonate loss) and stimulate respiration. However, supporting data have been lacking for this practice. A case control study demonstrated no reduction in mechanical ventilation days using 500 mg/day of acetazolamide [<a href="#rid68">68</a>]. After pharmacodynamic modeling suggested that higher doses might be necessary [<a href="#rid69">69</a>], a multi-center, randomized clinical trial was undertaken to explore the use of higher dose acetazolamide, but 500 to 1000 mg twice daily again failed to demonstrate any significant reduction in duration of IMV [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1790698225"><span class="h2">High flow nasal cannula oxygen</span><span class="headingEndMark"> — </span>There has been a growing trend to utilize high flow nasal cannula oxygen as an ancillary treatment for avoiding reintubation following liberation from mechanical ventilation. Proposed mechanisms of benefit include wash-out of the anatomical deadspace and mitigation of carbon dioxide rebreathing, increased nasopharyngeal pressure and intrinsic PEEP, improved conductance and compliance, and attenuated inspiratory resistance [<a href="#rid70">70-72</a>]. Demonstrated benefits in patients with COPD have included reduced respiratory rates, increased tidal volumes, reduced minute ventilation, reduced pCO<sub>2</sub> and transcutaneous CO<sub>2</sub>, and a reduction in the rapid shallow breathing index and work of breathing [<a href="#rid73">73-75</a>]. Compared with conventional low flow oxygen, reduced reintubation rates have been reported with the routine application of HFNC following extubation in patients at low risk for reintubation (excluding moderate to severe COPD) [<a href="#rid76">76</a>]. Compared with NIV, HFNC has been shown to be equivalent in reducing the need for reintubation within 72 hours among high-risk patients (20 percent of which had moderate to severe COPD) [<a href="#rid77">77</a>]. In a prospective cohort comparing HFNC to noninvasive ventilation (NIV) in COPD patients with moderate hypercapnic acute respiratory failure, the extubation failure rate with HFNC (28.2 percent) was found to be not statistically less than that of NIV (39.5 percent), but skin breakdown issues and required nursing airway interventions were significantly less common in the HFNC group [<a href="#rid78">78</a>]. The role of HFNC postextubation and technical aspects of high flow oxygen are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114077.html" rel="external">"Heated and humidified high-flow nasal oxygen in adults: Practical considerations and potential applications"</a> and  <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">"Extubation management in the adult intensive care unit", section on 'Low-flow versus high-flow oxygen'</a> and  <a class="medical medical_review" href="/z/d/html/1634.html" rel="external">"Extubation management in the adult intensive care unit", section on 'High-flow oxygen via nasal cannulae'</a>.)</p><p class="headingAnchor" id="H585471"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Mechanical ventilation for acute respiratory failure in patients with chronic obstructive pulmonary disease (COPD) is associated with high rates of intensive care unit (ICU) mortality (37 to 64 percent) [<a href="#rid79">79-83</a>]. A one year retrospective study of 4791 patients demonstrated that among COPD patients with long-term oxygen dependence who received IMV for AECOPD, in-hospital mortality was 23 percent. Among those surviving to discharge, 27 percent were in a skilled nursing facility within 30 days, and within 12 months, 67 percent were readmitted at least once, and 59 percent were dead [<a href="#rid84">84</a>]. A smaller observational study of less severe COPD patients requiring IMV reported a slightly lower in-hospital mortality (17 percent), and a lower rate of readmission (21 percent [<a href="#rid85">85</a>]). In addition, the ability of patients with COPD to successfully be liberated from mechanical ventilation is poorly studied [<a href="#rid86">86</a>]. Prognosis appears to be affected by both the severity of the underlying COPD as well as the reason for mechanical ventilation. Poor prognostic factors in this population include failure of noninvasive ventilation, the presence of multiorgan failure and virulent pathogens such as <em>Pseudomonas</em> and <em>Aspergillus</em> spp. While earlier studies suggested that mortality was determined by the severity of the underlying disease (eg, multiorgan failure, acute respiratory distress syndrome, and high Acute Physiologic and Chronic Health Evaluation [APACHE] score), several studies have since reported that a diagnosis of COPD alone is also a risk factor for death in mechanically ventilated patients:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 670 patients reported a significantly higher mortality in COPD patients with a higher acute physiologic and chronic health evaluation (APACHE) score or active malignancy [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one retrospective study of 428 patients with acute respiratory failure due to community acquired pneumonia, compared to patients without COPD, patients with COPD had a higher rate of requiring mechanical ventilation (odds ratio [OR] 2.78, 95% CI 1.6-4.7) and of dying (OR 1.58, 95% CI 1.0-1.4) [<a href="#rid80">80</a>]. The highest mortality was observed in intubated patients with COPD who had failed noninvasive ventilation (50 percent). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective observational study of 235 patients mechanically ventilated for respiratory failure, compared to patients without a diagnosis of COPD, a diagnosis of COPD was an independent predictor of mortality (hazard ratio, 2.1; 95% CI 1.1-3.9) [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two observational studies of patients with ventilator-associated pneumonia, compared to patients without COPD, patients with COPD had higher rates of ICU mortality (64 versus 28 percent), and a longer duration of mechanical ventilation (24 versus 13 days) and ICU stay (26 versus 15 days) [<a href="#rid82">82,87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective analysis of 279 patients with ICU-acquired pneumonia demonstrated that 90 day mortality was higher in patients with COPD (57 percent) compared to those without COPD (37 percent) [<a href="#rid88">88</a>].</p><p></p><p>Infection with emerging pathogens, such as <em>Pseudomonas</em> and <em>Aspergillus</em> spp, may also be associated with high mortality in patients mechanically ventilated for acute respiratory failure and COPD [<a href="#rid80">80,89-93</a>]. COPD has been associated with an increased risk of MRSA and pseudomonas pneumonia [<a href="#rid94">94</a>] and a higher rate of infection with Aspergillus species [<a href="#rid88">88</a>] among patients with healthcare-associated pneumonia. The emergence of these organisms in COPD may be in part due to the high rate of initial empiric antibiotic and glucocorticoid therapy that is common in this population [<a href="#rid89">89,95,96</a>]. In particular, when the infection with <em>Aspergillus</em> spp is detected and treated late in its course, the mortality is thought to range from 80 to 100 percent [<a href="#rid89">89,97</a>]. (See  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/z/d/html/7019.html" rel="external">"Management of infection in exacerbations of chronic obstructive pulmonary disease"</a>.) </p><p>Prognosis of AECOPD and acute respiratory distress syndrome (ARDS) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1601.html" rel="external">"Acute respiratory distress syndrome: Prognosis and outcomes in adults"</a> and  <a class="medical medical_review" href="/z/d/html/122145.html" rel="external">"COPD exacerbations: Prognosis, discharge planning, and prevention", section on 'Prognosis after an exacerbation'</a> and  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management"</a>.) </p><p class="headingAnchor" id="H673761311"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110267.html" rel="external">"Society guideline links: Chronic obstructive pulmonary disease"</a>.)</p><p class="headingAnchor" id="H14987278"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The decision to institute invasive mechanical ventilation in patients with acute respiratory failure complicating chronic obstructive pulmonary disease (COPD) is based upon a constellation of clinical signs and symptoms, all within the context of the patient's preferences for life support. Common indications for intubation in this population include respiratory distress, failure to respond clinically to noninvasive ventilation, and gas exchange impairment that is unresponsive to medical therapy and/or noninvasive ventilation (failure to oxygenate or ventilate). (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The primary objectives of mechanical ventilation in patients with COPD include supporting oxygenation and ventilation, minimizing the work of breathing, and avoiding dynamic hyperinflation (DHI). (See <a class="local">'Goals of ventilator management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who require mechanical ventilation for acute respiratory failure complicating COPD, we suggest volume-targeted modes of ventilation over pressure support or pressure-limited modes of ventilation. Among the volume-targeted modes, we prefer volume-controlled modes (eg, volume control-continuous mandatory ventilation) or synchronized intermittent mandatory ventilation with pressure support [SIMV/PSV] if volume-controlled modes result in hyperventilation. Switching modes is not uncommon during the course of a patient's illness, particularly when complications of mechanical ventilation occur. (See <a class="local">'Ventilator modes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ideal ventilator settings in patients with acute respiratory failure complicating COPD are those that meet the goals of mechanical ventilation. The initial ventilator settings will vary according to the cause of acute respiratory failure as well as the mode of mechanical ventilation selected. Subsequent adjustments should be made based upon the patient's clinical status, comfort level, gas exchange, and propensity for developing dynamic hyperinflation (DHI). Suggested initial ventilator settings are provided above. (See <a class="local">'Initial ventilator settings and monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intrinsic PEEP (also known as auto-PEEP) is common in patients with COPD who are mechanically ventilated, due to a high prevalence of spontaneous or ventilator-induced dynamic hyperinflation (DHI). Auto-PEEP can result in patient-ventilator dyssynchrony, increased work of breathing, barotrauma, cardiovascular collapse, and even death. (See <a class="local">'Dynamic hyperinflation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevention and treatment of DHI is primarily achieved through a reduction in respiratory rate and/or or tidal volume, raising the inspiratory flow rate, the application of extrinsic PEEP, and treating underlying airflow obstruction (if present) with bronchodilators and glucocorticoids. (See <a class="local">'Prevention and treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with COPD who are mechanically ventilated should also be treated for the primary cause of their respiratory failure. This is especially important for patients with severe airflow obstruction from acute exacerbations of COPD, who should be aggressively treated with bronchodilators, glucocorticoids and antibiotics. (See <a class="local">'Ancillary therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mortality of patients with COPD who are mechanically ventilated for acute respiratory failure is high (37 to 64 percent). Factors that portend a poor prognosis in this population include failure to respond to noninvasive ventilation, the presence of multiorgan failure, active malignancy, a high acute physiologic and chronic health evaluation (APACHE) score, and the presence of virulent pathogens such as <em>Pseudomonas</em> and <em>Aspergillus</em> species cultured from airway secretions. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.</a></li><li><a class="nounderline abstract_t">Evans TW. International Consensus Conferences in Intensive Care Medicine: non-invasive positive pressure ventilation in acute respiratory failure. Organised jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Société de Réanimation de Langue Française, and approved by the ATS Board of Directors, December 2000. Intensive Care Med 2001; 27:166.</a></li><li><a class="nounderline abstract_t">Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333:817.</a></li><li><a class="nounderline abstract_t">Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; :CD004104.</a></li><li><a class="nounderline abstract_t">Keenan SP, Sinuff T, Cook DJ, Hill NS. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. Ann Intern Med 2003; 138:861.</a></li><li><a class="nounderline abstract_t">Confalonieri M, Garuti G, Cattaruzza MS, et al. A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation. Eur Respir J 2005; 25:348.</a></li><li><a class="nounderline abstract_t">Stefan MS, Shieh MS, Pekow PS, et al. Trends in mechanical ventilation among patients hospitalized with acute exacerbations of COPD in the United States, 2001 to 2011. Chest 2015; 147:959.</a></li><li><a class="nounderline abstract_t">Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372:2185.</a></li><li><a class="nounderline abstract_t">Slutsky AS. Mechanical ventilation. American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833.</a></li><li><a class="nounderline abstract_t">Tobin MJ, Perez W, Guenther SM, et al. Does rib cage-abdominal paradox signify respiratory muscle fatigue? J Appl Physiol (1985) 1987; 63:851.</a></li><li><a class="nounderline abstract_t">Shorr AF, Sun X, Johannes RS, et al. Validation of a novel risk score for severity of illness in acute exacerbations of COPD. Chest 2011; 140:1177.</a></li><li><a class="nounderline abstract_t">Tabak YP, Sun X, Johannes RS, et al. Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score. Arch Intern Med 2009; 169:1595.</a></li><li><a class="nounderline abstract_t">Phua J, Kong K, Lee KH, et al. Noninvasive ventilation in hypercapnic acute respiratory failure due to chronic obstructive pulmonary disease vs. other conditions: effectiveness and predictors of failure. Intensive Care Med 2005; 31:533.</a></li><li><a class="nounderline abstract_t">Carratù P, Bonfitto P, Dragonieri S, et al. Early and late failure of noninvasive ventilation in chronic obstructive pulmonary disease with acute exacerbation. Eur J Clin Invest 2005; 35:404.</a></li><li><a class="nounderline abstract_t">Lindenauer PK, Stefan MS, Shieh MS, et al. Hospital patterns of mechanical ventilation for patients with exacerbations of COPD. Ann Am Thorac Soc 2015; 12:402.</a></li><li><a class="nounderline abstract_t">Davidson AC, Banham S, Elliott M, et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults. Thorax 2016; 71 Suppl 2:ii1.</a></li><li><a class="nounderline abstract_t">Chatburn RL, El-Khatib M, Mireles-Cabodevila E. A taxonomy for mechanical ventilation: 10 fundamental maxims. Respir Care 2014; 59:1747.</a></li><li><a class="nounderline abstract_t">Leung P, Jubran A, Tobin MJ. Comparison of assisted ventilator modes on triggering, patient effort, and dyspnea. Am J Respir Crit Care Med 1997; 155:1940.</a></li><li><a class="nounderline abstract_t">Tobin MJ, Jubran A, Laghi F. Patient-ventilator interaction. Am J Respir Crit Care Med 2001; 163:1059.</a></li><li><a class="nounderline abstract_t">Ward ME, Corbeil C, Gibbons W, et al. Optimization of respiratory muscle relaxation during mechanical ventilation. Anesthesiology 1988; 69:29.</a></li><li><a class="nounderline abstract_t">Marini JJ, Smith TC, Lamb VJ. External work output and force generation during synchronized intermittent mechanical ventilation. Effect of machine assistance on breathing effort. Am Rev Respir Dis 1988; 138:1169.</a></li><li><a class="nounderline abstract_t">Imsand C, Feihl F, Perret C, Fitting JW. Regulation of inspiratory neuromuscular output during synchronized intermittent mechanical ventilation. Anesthesiology 1994; 80:13.</a></li><li><a class="nounderline abstract_t">Esteban A, Frutos F, Tobin MJ, et al. A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group. N Engl J Med 1995; 332:345.</a></li><li><a class="nounderline abstract_t">Kreit JW, Capper MW, Eschenbacher WL. Patient work of breathing during pressure support and volume-cycled mechanical ventilation. Am J Respir Crit Care Med 1994; 149:1085.</a></li><li><a class="nounderline abstract_t">Parthasarathy S, Jubran A, Tobin MJ. Cycling of inspiratory and expiratory muscle groups with the ventilator in airflow limitation. Am J Respir Crit Care Med 1998; 158:1471.</a></li><li><a class="nounderline abstract_t">Marini JJ, Crooke PS 3rd, Truwit JD. Determinants and limits of pressure-preset ventilation: a mathematical model of pressure control. J Appl Physiol (1985) 1989; 67:1081.</a></li><li><a class="nounderline abstract_t">Jubran A, Van de Graaff WB, Tobin MJ. Variability of patient-ventilator interaction with pressure support ventilation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:129.</a></li><li><a class="nounderline abstract_t">Girault C, Richard JC, Chevron V, et al. Comparative physiologic effects of noninvasive assist-control and pressure support ventilation in acute hypercapnic respiratory failure. Chest 1997; 111:1639.</a></li><li><a class="nounderline abstract_t">O'Donnell DE, D'Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med 2002; 166:663.</a></li><li><a class="nounderline abstract_t">Díaz O, Villafranca C, Ghezzo H, et al. Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur Respir J 2001; 17:1120.</a></li><li><a class="nounderline abstract_t">Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet 2018; 391:1693.</a></li><li><a class="nounderline abstract_t">Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018; 363:k4169.</a></li><li><a class="nounderline abstract_t">Jubran A, Tobin MJ. Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients. Chest 1990; 97:1420.</a></li><li><a class="nounderline abstract_t">Laghi F, Karamchandani K, Tobin MJ. Influence of ventilator settings in determining respiratory frequency during mechanical ventilation. Am J Respir Crit Care Med 1999; 160:1766.</a></li><li><a class="nounderline abstract_t">Laghi F, Segal J, Choe WK, Tobin MJ. Effect of imposed inflation time on respiratory frequency and hyperinflation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1365.</a></li><li><a class="nounderline abstract_t">Connors AF Jr, McCaffree DR, Gray BA. Effect of inspiratory flow rate on gas exchange during mechanical ventilation. Am Rev Respir Dis 1981; 124:537.</a></li><li><a class="nounderline abstract_t">Fernandez R, Mendez M, Younes M. Effect of ventilator flow rate on respiratory timing in normal humans. Am J Respir Crit Care Med 1999; 159:710.</a></li><li><a class="nounderline abstract_t">Puddy A, Younes M. Effect of inspiratory flow rate on respiratory output in normal subjects. Am Rev Respir Dis 1992; 146:787.</a></li><li><a class="nounderline abstract_t">Sassoon CS, Del Rosario N, Fei R, et al. Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work. Crit Care Med 1994; 22:1933.</a></li><li><a class="nounderline abstract_t">Giuliani R, Mascia L, Recchia F, et al. Patient-ventilator interaction during synchronized intermittent mandatory ventilation. Effects of flow triggering. Am J Respir Crit Care Med 1995; 151:1.</a></li><li><a class="nounderline abstract_t">Aslanian P, El Atrous S, Isabey D, et al. Effects of flow triggering on breathing effort during partial ventilatory support. Am J Respir Crit Care Med 1998; 157:135.</a></li><li><a class="nounderline abstract_t">MacIntyre NR, Cheng KC, McConnell R. Applied PEEP during pressure support reduces the inspiratory threshold load of intrinsic PEEP. Chest 1997; 111:188.</a></li><li><a class="nounderline abstract_t">Coussa ML, Guérin C, Eissa NT, et al. Partitioning of work of breathing in mechanically ventilated COPD patients. J Appl Physiol (1985) 1993; 75:1711.</a></li><li><a class="nounderline abstract_t">de Chazal I, Hubmayr RD. Novel aspects of pulmonary mechanics in intensive care. Br J Anaesth 2003; 91:81.</a></li><li><a class="nounderline abstract_t">Thorevska NY, Manthous CA. Determinants of dynamic hyperinflation in a bench model. Respir Care 2004; 49:1326.</a></li><li><a class="nounderline abstract_t">Petrof BJ, Legaré M, Goldberg P, et al. Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 141:281.</a></li><li><a class="nounderline abstract_t">Ranieri VM, Mascia L, Petruzzelli V, et al. Inspiratory effort and measurement of dynamic intrinsic PEEP in COPD patients: effects of ventilator triggering systems. Intensive Care Med 1995; 21:896.</a></li><li><a class="nounderline abstract_t">Pepe PE, Marini JJ. Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect. Am Rev Respir Dis 1982; 126:166.</a></li><li><a class="nounderline abstract_t">Caramez MP, Borges JB, Tucci MR, et al. Paradoxical responses to positive end-expiratory pressure in patients with airway obstruction during controlled ventilation. Crit Care Med 2005; 33:1519.</a></li><li><a class="nounderline abstract_t">Tuxen DV, Lane S. The effects of ventilatory pattern on hyperinflation, airway pressures, and circulation in mechanical ventilation of patients with severe air-flow obstruction. Am Rev Respir Dis 1987; 136:872.</a></li><li><a class="nounderline abstract_t">de Durante G, del Turco M, Rustichini L, et al. ARDSNet lower tidal volume ventilatory strategy may generate intrinsic positive end-expiratory pressure in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165:1271.</a></li><li><a class="nounderline abstract_t">Marini JJ, Brower RG. Auto-peep with low tidal volume. Am J Respir Crit Care Med 2003; 167:1150.</a></li><li><a class="nounderline abstract_t">Marini JJ, Crooke PS 3rd. A general mathematical model for respiratory dynamics relevant to the clinical setting. Am Rev Respir Dis 1993; 147:14.</a></li><li><a class="nounderline abstract_t">Marini JJ, Rodriguez RM, Lamb V. The inspiratory workload of patient-initiated mechanical ventilation. Am Rev Respir Dis 1986; 134:902.</a></li><li><a class="nounderline abstract_t">Polese G, Massara A, Poggi R, et al. Flow-triggering reduces inspiratory effort during weaning from mechanical ventilation. Intensive Care Med 1995; 21:682.</a></li><li><a class="nounderline abstract_t">Sassoon CS, Lodia R, Rheeman CH, et al. Inspiratory muscle work of breathing during flow-by, demand-flow, and continuous-flow systems in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:1219.</a></li><li><a class="nounderline abstract_t">Chatburn RL, Mireles-Cabodevila E. 2019 Year in Review: Patient-Ventilator Synchrony. Respir Care 2020; 65:558.</a></li><li><a class="nounderline abstract_t">Smith TC, Marini JJ. Impact of PEEP on lung mechanics and work of breathing in severe airflow obstruction. J Appl Physiol (1985) 1988; 65:1488.</a></li><li><a class="nounderline abstract_t">Ranieri VM, Giuliani R, Cinnella G, et al. Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation. Am Rev Respir Dis 1993; 147:5.</a></li><li><a class="nounderline abstract_t">Faisy C, Meziani F, Planquette B, et al. Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. JAMA 2016; 315:480.</a></li><li><a class="nounderline abstract_t">Dhand R, Duarte AG, Jubran A, et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med 1996; 154:388.</a></li><li><a class="nounderline abstract_t">Dhand R, Tobin MJ. Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients. Eur Respir J 1996; 9:585.</a></li><li><a class="nounderline abstract_t">Duarte AG, Dhand R, Reid R, et al. Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration. Am J Respir Crit Care Med 1996; 154:1658.</a></li><li><a class="nounderline abstract_t">Duarte AG, Fink JB, Dhand R. Inhalation therapy during mechanical ventilation. Respir Care Clin N Am 2001; 7:233.</a></li><li><a class="nounderline abstract_t">Holland A, Smith F, Penny K, et al. Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units. Cochrane Database Syst Rev 2013; :CD008863.</a></li><li><a class="nounderline abstract_t">Alía I, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171:1939.</a></li><li><a class="nounderline abstract_t">Hashemian SM, Mortaz E, Jamaati H, et al. Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells. J Crit Care 2018; 44:161.</a></li><li><a class="nounderline abstract_t">Bahloul M, Chaari A, Tounsi A, et al. Impact of acetazolamide use in severe exacerbation of chronic obstructive pulmonary disease requiring invasive mechanical ventilation. Int J Crit Illn Inj Sci 2015; 5:3.</a></li><li><a class="nounderline abstract_t">Heming N, Urien S, Fulda V, et al. Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients. PLoS One 2014; 9:e86313.</a></li><li><a class="nounderline abstract_t">Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med 2009; 103:1400.</a></li><li><a class="nounderline abstract_t">Atwood CW Jr, Camhi S, Little KC, et al. Impact of Heated Humidified High Flow Air via Nasal Cannula on Respiratory Effort in Patients with Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis 2017; 4:279.</a></li><li><a class="nounderline abstract_t">Möller W, Feng S, Domanski U, et al. Nasal high flow reduces dead space. J Appl Physiol (1985) 2017; 122:191.</a></li><li><a class="nounderline abstract_t">Bräunlich J, Köhler M, Wirtz H. Nasal highflow improves ventilation in patients with COPD. Int J Chron Obstruct Pulmon Dis 2016; 11:1077.</a></li><li><a class="nounderline abstract_t">Di Mussi R, Spadaro S, Stripoli T, et al. High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease. Crit Care 2018; 22:180.</a></li><li><a class="nounderline abstract_t">Pisani L, Betti S, Biglia C, et al. Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study. BMC Pulm Med 2020; 20:12.</a></li><li><a class="nounderline abstract_t">Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA 2016; 315:1354.</a></li><li><a class="nounderline abstract_t">Hernández G, Vaquero C, Colinas L, et al. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA 2016; 316:1565.</a></li><li><a class="nounderline abstract_t">Sun J, Li Y, Ling B, et al. High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study. Int J Chron Obstruct Pulmon Dis 2019; 14:1229.</a></li><li><a class="nounderline abstract_t">Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274:1852.</a></li><li><a class="nounderline abstract_t">Rello J, Rodriguez A, Torres A, et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 2006; 27:1210.</a></li><li><a class="nounderline abstract_t">Rodríguez A, Lisboa T, Solé-Violán J, et al. Impact of nonexacerbated COPD on mortality in critically ill patients. Chest 2011; 139:1354.</a></li><li><a class="nounderline abstract_t">Makris D, Desrousseaux B, Zakynthinos E, et al. The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia. Respir Med 2011; 105:1022.</a></li><li><a class="nounderline abstract_t">Afessa B, Morales IJ, Scanlon PD, Peters SG. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med 2002; 30:1610.</a></li><li><a class="nounderline abstract_t">Hajizadeh N, Goldfeld K, Crothers K. What happens to patients with COPD with long-term oxygen treatment who receive mechanical ventilation for COPD exacerbation? A 1-year retrospective follow-up study. Thorax 2015; 70:294.</a></li><li><a class="nounderline abstract_t">Gadre SK, Duggal A, Mireles-Cabodevila E, et al. Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD). Medicine (Baltimore) 2018; 97:e0487.</a></li><li><a class="nounderline abstract_t">Peñuelas O, Frutos-Vivar F, Fernández C, et al. Characteristics and outcomes of ventilated patients according to time to liberation from mechanical ventilation. Am J Respir Crit Care Med 2011; 184:430.</a></li><li><a class="nounderline abstract_t">Nseir S, Di Pompeo C, Soubrier S, et al. Impact of ventilator-associated pneumonia on outcome in patients with COPD. Chest 2005; 128:1650.</a></li><li><a class="nounderline abstract_t">Rinaudo M, Ferrer M, Terraneo S, et al. Impact of COPD in the outcome of ICU-acquired pneumonia with and without previous intubation. Chest 2015; 147:1530.</a></li><li><a class="nounderline abstract_t">Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005; 11:427.</a></li><li><a class="nounderline abstract_t">Hedayati MT, Khodavaisy S, Alialy M, et al. Invasive aspergillosis in intensive care unit patients in Iran. Acta Medica (Hradec Kralove) 2013; 56:52.</a></li><li><a class="nounderline abstract_t">Domenech A, Puig C, Martí S, et al. Infectious etiology of acute exacerbations in severe COPD patients. J Infect 2013; 67:516.</a></li><li><a class="nounderline abstract_t">Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter 2013; 26:173.</a></li><li><a class="nounderline abstract_t">Fernández-Ruiz M, Silva JT, San-Juan R, et al. Aspergillus tracheobronchitis: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91:261.</a></li><li><a class="nounderline abstract_t">Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 2016; 21:157.</a></li><li><a class="nounderline abstract_t">Vogeser M, Wanders A, Haas A, Ruckdeschel G. A four-year review of fatal Aspergillosis. Eur J Clin Microbiol Infect Dis 1999; 18:42.</a></li><li><a class="nounderline abstract_t">Agustí C, Rañó A, Filella X, et al. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest 2003; 123:488.</a></li><li><a class="nounderline abstract_t">Bulpa PA, Dive AM, Garrino MG, et al. Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care? Intensive Care Med 2001; 27:59.</a></li></ol></div><div id="topicVersionRevision">Topic 1632 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15219010" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11280630" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : International Consensus Conferences in Intensive Care Medicine: non-invasive positive pressure ventilation in acute respiratory failure. Organised jointly by the American Thoracic Society, the European Respiratory Society, the European Society of Intensive Care Medicine, and the Sociétéde Réanimation de Langue Française, and approved by the ATS Board of Directors, December 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651472" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266518" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12779296" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684302" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A chart of failure risk for noninvasive ventilation in patients with COPD exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25375230" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in mechanical ventilation among patients hospitalized with acute exacerbations of COPD in the United States, 2001 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981908" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8252973" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanical ventilation. American College of Chest Physicians' Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3654445" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Does rib cage-abdominal paradox signify respiratory muscle fatigue?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21527510" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Validation of a novel risk score for severity of illness in acute exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786679" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mortality and need for mechanical ventilation in acute exacerbations of chronic obstructive pulmonary disease: development and validation of a simple risk score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742175" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Noninvasive ventilation in hypercapnic acute respiratory failure due to chronic obstructive pulmonary disease vs. other conditions: effectiveness and predictors of failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15948902" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Early and late failure of noninvasive ventilation in chronic obstructive pulmonary disease with acute exacerbation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25654431" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hospital patterns of mechanical ventilation for patients with exacerbations of COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976648" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25118309" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A taxonomy for mechanical ventilation: 10 fundamental maxims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196100" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Comparison of assisted ventilator modes on triggering, patient effort, and dyspnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316635" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Patient-ventilator interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3389564" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Optimization of respiratory muscle relaxation during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3202477" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : External work output and force generation during synchronized intermittent mechanical ventilation. Effect of machine assistance on breathing effort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8291702" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Regulation of inspiratory neuromuscular output during synchronized intermittent mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7823995" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A comparison of four methods of weaning patients from mechanical ventilation. Spanish Lung Failure Collaborative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8173745" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Patient work of breathing during pressure support and volume-cycled mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9817695" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cycling of inspiratory and expiratory muscle groups with the ventilator in airflow limitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2676950" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Determinants and limits of pressure-preset ventilation: a mathematical model of pressure control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599811" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Variability of patient-ventilator interaction with pressure support ventilation in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9187187" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Comparative physiologic effects of noninvasive assist-control and pressure support ventilation in acute hypercapnic respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12204862" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11491153" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29726345" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30355567" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oxygen therapy for acutely ill medical patients: a clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2347228" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Reliability of pulse oximetry in titrating supplemental oxygen therapy in ventilator-dependent patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556154" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Influence of ventilator settings in determining respiratory frequency during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11371402" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of imposed inflation time on respiratory frequency and hyperinflation in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7305107" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effect of inspiratory flow rate on gas exchange during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10051241" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of ventilator flow rate on respiratory timing in normal humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519864" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effect of inspiratory flow rate on respiratory output in normal subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7988129" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7812537" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patient-ventilator interaction during synchronized intermittent mandatory ventilation. Effects of flow triggering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445291" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Effects of flow triggering on breathing effort during partial ventilatory support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996015" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Applied PEEP during pressure support reduces the inspiratory threshold load of intrinsic PEEP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8282624" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Partitioning of work of breathing in mechanically ventilated COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821568" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Novel aspects of pulmonary mechanics in intensive care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15507167" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Determinants of dynamic hyperinflation in a bench model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2405757" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636521" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Inspiratory effort and measurement of dynamic intrinsic PEEP in COPD patients: effects of ventilator triggering systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046541" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Occult positive end-expiratory pressure in mechanically ventilated patients with airflow obstruction: the auto-PEEP effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003057" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Paradoxical responses to positive end-expiratory pressure in patients with airway obstruction during controlled ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662241" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effects of ventilatory pattern on hyperinflation, airway pressures, and circulation in mechanical ventilation of patients with severe air-flow obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11991877" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : ARDSNet lower tidal volume ventilatory strategy may generate intrinsic positive end-expiratory pressure in patients with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12684254" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Auto-peep with low tidal volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420408" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A general mathematical model for respiratory dynamics relevant to the clinical setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3096177" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The inspiratory workload of patient-initiated mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8522675" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Flow-triggering reduces inspiratory effort during weaning from mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1586070" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Inspiratory muscle work of breathing during flow-by, demand-flow, and continuous-flow systems in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213603" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : 2019 Year in Review: Patient-Ventilator Synchrony.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3053583" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of PEEP on lung mechanics and work of breathing in severe airflow obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420430" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Physiologic effects of positive end-expiratory pressure in patients with chronic obstructive pulmonary disease during acute ventilatory failure and controlled mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26836730" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756811" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730023" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bronchodilator delivery with metered-dose inhalers in mechanically-ventilated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8970351" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517022" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Inhalation therapy during mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740736" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123804" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29127842" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Budesonide facilitates weaning from mechanical ventilation in difficult-to-wean very severe COPD patients: Association with inflammatory mediators and cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810957" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Impact of acetazolamide use in severe exacerbation of chronic obstructive pulmonary disease requiring invasive mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24466018" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19467849" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Research in high flow therapy: mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29354672" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impact of Heated Humidified High Flow Air via Nasal Cannula on Respiratory Effort in Patients with Chronic Obstructive Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27856714" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nasal high flow reduces dead space.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307723" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Nasal highflow improves ventilation in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30071876" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : High-flow nasal cannula oxygen therapy decreases postextubation neuroventilatory drive and work of breathing in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31931776" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Effects of high-flow nasal cannula in patients with persistent hypercapnia after an acute COPD exacerbation: a prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26975498" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706464" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31239658" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : High flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease with acute-moderate hypercapnic respiratory failure: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7500534" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510452" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393392" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Impact of nonexacerbated COPD on mortality in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21435855" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The impact of COPD on ICU mortality in patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130987" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24826845" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : What happens to patients with COPD with long-term oxygen treatment who receive mechanical ventilation for COPD exacerbation? A 1-year retrospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29703009" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Acute respiratory failure requiring mechanical ventilation in severe chronic obstructive pulmonary disease (COPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616997" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Characteristics and outcomes of ventilated patients according to time to liberation from mechanical ventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16162771" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of ventilator-associated pneumonia on outcome in patients with COPD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25612147" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Impact of COPD in the outcome of ICU-acquired pneumonia with and without previous intubation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882191" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24069658" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Invasive aspergillosis in intensive care unit patients in Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24055804" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Infectious etiology of acute exacerbations in severe COPD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817660" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22932790" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Aspergillus tracheobronchitis: report of 8 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682638" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192713" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A four-year review of fatal Aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576371" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11280674" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
